Abstract：【Objective】To evaluate the efficacy, complications and adverse reactions of HHT (homoharringtonine)contained regimen in patients with acute myeloid leukemia (AML) by meta analysis.【Methods】 A collection of clinical trials for the treatment of AML HHT was performed through searching the PubMed, the Cochrane Library, EMbase, VIP, WanFang Data, CBM and CNKI databases from inception to January 2015. According to the inclusion and exclusion criteria, two researchers were selected to carry out the research of literature selection, data extraction and evaluation. The Meta analysis was conducted by using RevMan 5.2 software.【Results】 Seven trials involving in a total of 1,051 patients were included. The results of metaanalysis showed that: the HHT group was superior to the DA group in terms of CR（complete remission） rate and 3years EFS（event free survival）rate(P<0.05), but the difference of complications such as white blood cell reduction, bleeding, and infection rates was not statistically significant compared with the DA group (P>0.05); The incidence of adverse reactions such as cardiac injury was significantly lower than that of the DA group. 【Conclusion】 HHT containing regimen is safe and effective for the treatment of AML, and does not increase the incidence of complications. With easy access and low prices, HHT is a good choice for the treatment of AML and is worthy of clinical application.
2016, Vol. 33 
